Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 gene amplification.
Bicycle Therapeutics Lead Cancer Drug Combined With Merck’s Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
